<p>Prime Medicine, Inc. (NYSE:PRME - 获取免费报告) 的股价在周三交易中上涨了 7.5%。该股最高交易价格为 4.05 美元，最后交易价格为 3.9770 美元。在午盘交易中，成交量为 2,350,337 股，较平均交易量 3,235,643 股下降了 27%。该股此前收盘价为 3.70 美元。</p>
<p>获取 <strong>Prime Medicine</strong> 的提醒：</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>2024 年值得关注的两只基因编辑股票</li>
</ul>
<p>几家研究公司最近对 PRME 发布了报告。花旗集团将 Prime Medicine 的目标股价从 5.00 美元下调至 4.25 美元，并在 11 月 11 日的研究报告中对该股给予了 “中性” 评级。Chardan Capital 将 Prime Medicine 的目标股价从 10.00 美元下调至 9.00 美元，并在 11 月 10 日的报告中给予该股 “买入” 评级。Lifesci Capital 在 12 月 23 日的研究报告中开始覆盖 Prime Medicine，给予 “跑赢大盘” 评级，目标股价为 6.00 美元。最后，Wedbush 在 11 月 10 日的研究报告中重申了 “跑赢大盘” 评级，并将 Prime Medicine 的目标股价设定为 8.00 美元。四位分析师对该股给予了买入评级，三位分析师对该公司给予了持有评级。根据 MarketBeat.com 的数据，Prime Medicine 目前的共识评级为 “适度买入”，共识目标股价为 7.21 美元。</p>
<p><strong>阅读我们关于 PRME 的最新研究报告</strong></p>
<h2>Prime Medicine 股价上涨 10.9%</h2>
<p>该公司的 50 日简单移动平均线为 3.81 美元，200 日简单移动平均线为 4.14 美元。该股市值为 7.41 亿美元，市盈率为-2.00，贝塔值为 2.71。</p>
<h2>对 Prime Medicine 的对冲基金观点</h2>
<p>一些机构投资者和对冲基金最近买入和卖出了 PRME 的股票。Alphabet Inc.在第三季度将其在 Prime Medicine 的股份增加了 10.0%。Alphabet Inc.目前拥有 16,562,498 股该公司的股票，价值 91,756,000 美元，此前在上个季度购买了额外的 1,500,000 股。ARK Investment Management LLC 在第三季度将其在 Prime Medicine 的持股增加了 135.8%。ARK Investment Management LLC 目前拥有 5,477,851 股该公司的股票，价值 30,347,000 美元，此前在上个季度购买了额外的 3,155,182 股。Vanguard Group Inc.在第三季度将其在 Prime Medicine 的持股增加了 35.7%。Vanguard Group Inc.目前拥有 4,921,865 股该公司的股票，价值 27,267,000 美元，此前在该期间购买了额外的 1,294,355 股。Farallon Capital Management LLC 在第三季度将其在 Prime Medicine 的持股增加了 533.3%。Farallon Capital Management LLC 目前拥有 4,750,000 股该公司的股票，价值 26,315,000 美元，此前在上个季度收购了额外的 4,000,000 股。最后，Sumitomo Mitsui Trust Group Inc.在第三季度将其在 Prime Medicine 的持股增加了 127.7%。Sumitomo Mitsui Trust Group Inc.目前拥有 3,629,924 股该公司的股票，价值 20,110,000 美元，此前在该期间收购了额外的 2,035,406 股。机构投资者和对冲基金持有该公司 70.37% 的股份。</p>
<h2>关于 Prime Medicine</h2>
<p>(获取免费报告)</p>
<p>Prime Medicine, Inc. NYSE: PRME 是一家临床阶段的基因治疗公司，专注于利用先进的 CRISPR 衍生基因编辑技术——原编辑的潜力。通过完善精确修正致病突变所需的工具，Prime Medicine 旨在开发针对疾病潜在遗传驱动因素的单剂量治疗。该公司应用其专有的工程和递送平台，以优化靶向效率并最小化非靶向效应，使其在下一代基因编辑治疗领域处于领先地位。</p>
<p>Prime Medicine 的研发工作涵盖多个治疗领域，包括罕见遗传疾病、免疫肿瘤学和自身免疫疾病。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票，胜过 Prime Medicine</li>
<li>Elon 将 SpaceX 上市！$100 的首次公开募股机会！</li>
<li>请勿删除，立即阅读</li>
<li>你还认为白银是个笑话吗？看看接下来会发生什么。</li>
<li>将这些代码输入你的普通经纪账户</li>
<li>这只股票获得 94 分（满分 100 分）</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Prime Medicine 吗？</h2>
<p>在你考虑 Prime Medicine 之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Prime Medicine 并不在名单上。</p>
<p>虽然 Prime Medicine 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

PRME

<p>Prime Medicine (NYSE:PRME) 的股价上涨了 7.5%，达到 3.9770 美元，交易量为 2,350,337 股。分析师们的看法不一，花旗集团将其目标价从 5.00 美元下调至 4.25 美元，而 Chardan Capital 则设定了 9.00 美元的目标价。机构投资者持有该股票的 70.37%，包括 Alphabet Inc.和 ARK Investment Management 等公司的持股显著增加。Prime Medicine 专注于先进的基因编辑技术，旨在开发针对遗传疾病和其他疾病的治疗方案</p>

<p>Prime Medicine, Inc. (NYSE:PRME - Get Free Report)'s stock price traded up 7.5% during trading on Wednesday . The stock traded as high as $4.05 and last traded at $3.9770. 2,350,337 shares traded hands during mid-day trading, a decline of 27% from the average session volume of 3,235,643 shares. The stock had previously closed at $3.70.</p>
<div class="lb-trans"><p>Prime Medicine, Inc. (NYSE:PRME - 获取免费报告) 的股价在周三交易中上涨了 7.5%。该股最高交易价格为 4.05 美元，最后交易价格为 3.9770 美元。在午盘交易中，成交量为 2,350,337 股，较平均交易量 3,235,643 股下降了 27%。该股此前收盘价为 3.70 美元。</p>
</div><p>Get <strong>Prime Medicine</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Prime Medicine</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>2 gene editing stocks to keep on your 2024 watchlist</li>
</ul>
<div class="lb-trans"><ul>
<li>2024 年值得关注的两只基因编辑股票</li>
</ul>
</div><p>Several research firms recently issued reports on PRME. Citigroup reduced their price target on shares of Prime Medicine from $5.00 to $4.25 and set a &#34;neutral&#34; rating on the stock in a research report on Tuesday, November 11th. Chardan Capital reduced their target price on Prime Medicine from $10.00 to $9.00 and set a &#34;buy&#34; rating on the stock in a report on Monday, November 10th. Lifesci Capital initiated coverage on Prime Medicine in a research note on Tuesday, December 23rd. They issued an &#34;outperform&#34; rating and a $6.00 price target on the stock. Finally, Wedbush restated an &#34;outperform&#34; rating and set a $8.00 price objective on shares of Prime Medicine in a research report on Monday, November 10th. Four analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, Prime Medicine presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $7.21.</p>
<div class="lb-trans"><p>几家研究公司最近对 PRME 发布了报告。花旗集团将 Prime Medicine 的目标股价从 5.00 美元下调至 4.25 美元，并在 11 月 11 日的研究报告中对该股给予了 “中性” 评级。Chardan Capital 将 Prime Medicine 的目标股价从 10.00 美元下调至 9.00 美元，并在 11 月 10 日的报告中给予该股 “买入” 评级。Lifesci Capital 在 12 月 23 日的研究报告中开始覆盖 Prime Medicine，给予 “跑赢大盘” 评级，目标股价为 6.00 美元。最后，Wedbush 在 11 月 10 日的研究报告中重申了 “跑赢大盘” 评级，并将 Prime Medicine 的目标股价设定为 8.00 美元。四位分析师对该股给予了买入评级，三位分析师对该公司给予了持有评级。根据 MarketBeat.com 的数据，Prime Medicine 目前的共识评级为 “适度买入”，共识目标股价为 7.21 美元。</p>
</div><p><strong>Read Our Latest Research Report on PRME</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 PRME 的最新研究报告</strong></p>
</div><h2>Prime Medicine Stock Up 10.9%</h2>
<div class="lb-trans"><h2>Prime Medicine 股价上涨 10.9%</h2>
</div><p>The business's 50 day simple moving average is $3.81 and its two-hundred day simple moving average is $4.14. The stock has a market cap of $741.00 million, a P/E ratio of -2.00 and a beta of 2.71.</p>
<div class="lb-trans"><p>该公司的 50 日简单移动平均线为 3.81 美元，200 日简单移动平均线为 4.14 美元。该股市值为 7.41 亿美元，市盈率为-2.00，贝塔值为 2.71。</p>
</div><h2>Hedge Funds Weigh In On Prime Medicine</h2>
<div class="lb-trans"><h2>对 Prime Medicine 的对冲基金观点</h2>
</div><p>A number of institutional investors and hedge funds have recently bought and sold shares of PRME. Alphabet Inc. boosted its stake in shares of Prime Medicine by 10.0% during the third quarter. Alphabet Inc. now owns 16,562,498 shares of the company's stock valued at $91,756,000 after purchasing an additional 1,500,000 shares in the last quarter. ARK Investment Management LLC raised its holdings in Prime Medicine by 135.8% in the 3rd quarter. ARK Investment Management LLC now owns 5,477,851 shares of the company's stock valued at $30,347,000 after buying an additional 3,155,182 shares during the last quarter. Vanguard Group Inc. boosted its position in Prime Medicine by 35.7% during the 3rd quarter. Vanguard Group Inc. now owns 4,921,865 shares of the company's stock worth $27,267,000 after buying an additional 1,294,355 shares during the period. Farallon Capital Management LLC grew its holdings in Prime Medicine by 533.3% during the 3rd quarter. Farallon Capital Management LLC now owns 4,750,000 shares of the company's stock worth $26,315,000 after acquiring an additional 4,000,000 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its position in Prime Medicine by 127.7% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,629,924 shares of the company's stock valued at $20,110,000 after acquiring an additional 2,035,406 shares during the period. Institutional investors and hedge funds own 70.37% of the company's stock.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近买入和卖出了 PRME 的股票。Alphabet Inc.在第三季度将其在 Prime Medicine 的股份增加了 10.0%。Alphabet Inc.目前拥有 16,562,498 股该公司的股票，价值 91,756,000 美元，此前在上个季度购买了额外的 1,500,000 股。ARK Investment Management LLC 在第三季度将其在 Prime Medicine 的持股增加了 135.8%。ARK Investment Management LLC 目前拥有 5,477,851 股该公司的股票，价值 30,347,000 美元，此前在上个季度购买了额外的 3,155,182 股。Vanguard Group Inc.在第三季度将其在 Prime Medicine 的持股增加了 35.7%。Vanguard Group Inc.目前拥有 4,921,865 股该公司的股票，价值 27,267,000 美元，此前在该期间购买了额外的 1,294,355 股。Farallon Capital Management LLC 在第三季度将其在 Prime Medicine 的持股增加了 533.3%。Farallon Capital Management LLC 目前拥有 4,750,000 股该公司的股票，价值 26,315,000 美元，此前在上个季度收购了额外的 4,000,000 股。最后，Sumitomo Mitsui Trust Group Inc.在第三季度将其在 Prime Medicine 的持股增加了 127.7%。Sumitomo Mitsui Trust Group Inc.目前拥有 3,629,924 股该公司的股票，价值 20,110,000 美元，此前在该期间收购了额外的 2,035,406 股。机构投资者和对冲基金持有该公司 70.37% 的股份。</p>
</div><h2>About Prime Medicine</h2>
<div class="lb-trans"><h2>关于 Prime Medicine</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Prime Medicine, Inc NYSE: PRME is a clinical-stage genetic medicines company focused on harnessing the potential of prime editing, an advanced CRISPR-derived gene editing technology. By refining the tools required for precise correction of disease-causing mutations, Prime Medicine aims to develop single-dose treatments that address underlying genetic drivers of disease. The company applies its proprietary engineering and delivery platforms to optimize on-target efficiency and minimize off-target effects, positioning itself at the forefront of next-generation gene editing therapeutics.</p>
<div class="lb-trans"><p>Prime Medicine, Inc. NYSE: PRME 是一家临床阶段的基因治疗公司，专注于利用先进的 CRISPR 衍生基因编辑技术——原编辑的潜力。通过完善精确修正致病突变所需的工具，Prime Medicine 旨在开发针对疾病潜在遗传驱动因素的单剂量治疗。该公司应用其专有的工程和递送平台，以优化靶向效率并最小化非靶向效应，使其在下一代基因编辑治疗领域处于领先地位。</p>
</div><p>Prime Medicine's research and development efforts span multiple therapeutic areas, including rare genetic disorders, immuno-oncology, and autoimmune diseases.</p>
<div class="lb-trans"><p>Prime Medicine 的研发工作涵盖多个治疗领域，包括罕见遗传疾病、免疫肿瘤学和自身免疫疾病。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Prime Medicine</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>Do not delete, read immediately</li>
<li>You Still Think Silver’s a Joke? Watch What Happens Next.</li>
<li>Punch these codes into your ordinary brokerage account</li>
<li>This stock gets a 94 out of 100</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Prime Medicine</li>
<li>Elon 将 SpaceX 上市！$100 的首次公开募股机会！</li>
<li>请勿删除，立即阅读</li>
<li>你还认为白银是个笑话吗？看看接下来会发生什么。</li>
<li>将这些代码输入你的普通经纪账户</li>
<li>这只股票获得 94 分（满分 100 分）</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Prime Medicine Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Prime Medicine 吗？</h2>
</div><p>Before you consider Prime Medicine, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Prime Medicine 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prime Medicine wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Prime Medicine 并不在名单上。</p>
</div><p>While Prime Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Prime Medicine 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Prime Medicine（NYSE:PRME）股价上涨 7.5% - 接下来会如何发展？